Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCB Insights

The top 50 Latin America venture investors in 2026

View original at cbinsights.com
CB Insights - Enterprise Ai Title: The top 50 Latin America venture investors in 2026 Date: 2026-03-03 22:26 Source: https://www.cbinsights.com/research/the-top-50-latin-america-venture-investors/ <p><span style="font-weight: 400;">Latin America’s venture market is pulling back: deal volume has fallen by </span><a href…
Opening lines of the source · CB Insights · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Chile's 4 top-ranked VCs average just 9 years old

    80% confidence

  • With the majority of LatAm businesses being resource-constrained SMEs, AI tools help companies scale without adding headcount

    80% confidence

  • Brazil's top VCs kept 77% of their deals domestic, insulating local startups from cross-border capital slowdown

    80% confidence

  • Brazilian startups captured 60% of all deals from the region's top 50 investors

    80% confidence

  • Sales and customer service applications account for 35% of AI bets by top 3 LatAm VCs

    80% confidence

  • Fintech is emerging as the strongest contributor to LatAm's highest-quality venture portfolios

    80% confidence

  • LatAm's top investors are all-in on AI for sales and customer service, with top 3 VCs directing a quarter of their deals since 2023 to AI companies

    80% confidence

  • FCJ Venture Builder portfolio companies show 36% average M&A probability versus 21.6% global average

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com